Brought to you by 
PTC gets two rare disease therapies from Akcea
01 Sep 2020
Executive Summary
Ionis Pharmaceuticals Inc.’s Akcea Therapeutics Inc. licensed PTC Therapeutics Inc. exclusive rights to develop, manufacture, and commercialize its rare disease drugs Tegsedi (inotersen) and Waylivra (volanesorsen) in Latin America and certain Caribbean countries. Akcea has also granted PTC a right of first negotiation to commercialize AKCEA-TTR-LRx, a follow-on candidate to inotersen, on an exclusive basis in the territories.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PTC gets two rare disease therapies from Akcea
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice